Literature DB >> 22638770

Analysis of a Finnish family confirms RHBDF2 mutations as the underlying factor in tylosis with esophageal cancer.

Silva Saarinen1, Pia Vahteristo, Rainer Lehtonen, Kristiina Aittomäki, Virpi Launonen, Tuula Kiviluoto, Lauri A Aaltonen.   

Abstract

Tylosis with esophageal cancer (TOC) is a rare familial cancer syndrome inherited in an autosomal-dominant manner and characterized by esophageal cancer susceptibility and hyperkeratotic skin lesions. Two heterozygous missense mutations in the RHBDF2 gene were recently reported to be associated with TOC in three families: a p.Ile186Thr mutation was found in families from the UK and the US and a p.Pro189Leu mutation was detected in a German TOC family. We aimed to validate these novel results in an independent material by screening RHBDF2 in a previously unreported Finnish TOC family. We identified a new missense mutation, p.Asp188Asn, segregating with TOC in the Finnish family, and interestingly the detected mutation alters a codon located between the two previously reported mutation sites. Thus, we confirmed RHBDF2 mutations as the underlying cause of the TOC syndrome and our results suggest that the TOC associated mutations might be specific for this particular site in the RHBDF2 gene. These results enable the genetic counseling and diagnostic mutation screening of the members of TOC families.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22638770     DOI: 10.1007/s10689-012-9532-8

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  12 in total

Review 1.  Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas.

Authors:  H P Stevens; D P Kelsell; S P Bryant; D T Bishop; N K Spurr; J Weissenbach; D Marger; R S Marger; I M Leigh
Journal:  Arch Dermatol       Date:  1996-06

2.  Tylosis A with squamous cell carcinoma of the oesophagus in a Spanish family.

Authors:  Antonio Brage Varela; Marta María Blanco Rodríguez; Pamela Estévez Boullosa; Jesús García Silva
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-03       Impact factor: 2.566

3.  Tylosis esophageal cancer locus on chromosome 17q25.1 is commonly deleted in sporadic human esophageal cancer.

Authors:  T Iwaya; C Maesawa; S Ogasawara; G Tamura
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

4.  Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE.

Authors:  Colin Adrain; Markus Zettl; Yonka Christova; Neil Taylor; Matthew Freeman
Journal:  Science       Date:  2012-01-13       Impact factor: 47.728

5.  Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool family--a review of six generations.

Authors:  A Ellis; J K Field; E A Field; P S Friedmann; A Fryer; P Howard; I M Leigh; J Risk; J M Shaw; J Whittaker
Journal:  Eur J Cancer B Oral Oncol       Date:  1994

6.  Palmoplantar keratoderma in association with carcinoma of the esophagus maps to chromosome 17q distal to the keratin gene cluster.

Authors:  H C Hennies; M Hagedorn; A Reis
Journal:  Genomics       Date:  1995-09-20       Impact factor: 5.736

7.  Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q.

Authors:  M von Brevern; M C Hollstein; J M Risk; J Garde; W P Bennett; C C Harris; K R Muehlbauer; J K Field
Journal:  Oncogene       Date:  1998-10-22       Impact factor: 9.867

8.  Novel microsatellite markers and single nucleotide polymorphisms refine the tylosis with oesophageal cancer (TOC) minimal region on 17q25 to 42.5 kb: sequencing does not identify the causative gene.

Authors:  Joanne E Langan; Charlotte G Cole; Elisabeth J Huckle; Shaun Byrne; Fiona E McRonald; Lynn Rowbottom; Anthony Ellis; Joan M Shaw; Irene M Leigh; David P Kelsell; Ian Dunham; John K Field; Janet M Risk
Journal:  Hum Genet       Date:  2004-03-09       Impact factor: 4.132

9.  Characterization of a 500 kb region on 17q25 and the exclusion of candidate genes as the familial Tylosis Oesophageal Cancer (TOC) locus.

Authors:  Janet M Risk; Kathryn E Evans; Joanne Jones; Joanne E Langan; Lyn Rowbottom; Fiona E McRonald; Helen S Mills; Anthony Ellis; Joan M Shaw; Irene M Leigh; David P Kelsell; John K Field
Journal:  Oncogene       Date:  2002-09-12       Impact factor: 9.867

10.  Rhomboid family pseudoproteases use the ER quality control machinery to regulate intercellular signaling.

Authors:  Markus Zettl; Colin Adrain; Kvido Strisovsky; Viorica Lastun; Matthew Freeman
Journal:  Cell       Date:  2011-04-01       Impact factor: 41.582

View more
  19 in total

Review 1.  New lives for old: evolution of pseudoenzyme function illustrated by iRhoms.

Authors:  Colin Adrain; Matthew Freeman
Journal:  Nat Rev Mol Cell Biol       Date:  2012-07-11       Impact factor: 94.444

2.  Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease.

Authors:  Satoshi Kubo; Jill M Fritz; Hayley M Raquer-McKay; Rhea Kataria; Ivan Vujkovic-Cvijin; Ahmad Al-Shaibi; Yikun Yao; Lixin Zheng; Juan Zou; Alex D Waldman; Xinyi Jing; Taylor K Farley; Ann Y Park; Andrew J Oler; Adrian K Charles; Melanie Makhlouf; Eman H AbouMoussa; Reem Hasnah; Luis R Saraiva; Sundar Ganesan; Abdulrahman Ahmed Al-Subaiey; Helen Matthews; Emilio Flano; Hyun Hee Lee; Alexandra F Freeman; Asena Pınar Sefer; Ersin Sayar; Erkan Çakır; Elif Karakoc-Aydiner; Safa Baris; Yasmine Belkaid; Ahmet Ozen; Bernice Lo; Michael J Lenardo
Journal:  Nat Immunol       Date:  2021-12-22       Impact factor: 25.606

3.  Rhbdf2 mutations increase its protein stability and drive EGFR hyperactivation through enhanced secretion of amphiregulin.

Authors:  Vishnu Hosur; Kenneth R Johnson; Lisa M Burzenski; Timothy M Stearns; Richard S Maser; Leonard D Shultz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-13       Impact factor: 11.205

4.  iRhoms; Its Functions and Essential Roles.

Authors:  Min-Young Lee; Ki-Hoan Nam; Kyung-Chul Choi
Journal:  Biomol Ther (Seoul)       Date:  2016-03-01       Impact factor: 4.634

5.  Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17.

Authors:  Sathish K Maney; David R McIlwain; Robin Polz; Aleksandra A Pandyra; Balamurugan Sundaram; Dorit Wolff; Kazuhito Ohishi; Thorsten Maretzky; Matthew A Brooke; Astrid Evers; Ananda A Jaguva Vasudevan; Nima Aghaeepour; Jürgen Scheller; Carsten Münk; Dieter Häussinger; Tak W Mak; Garry P Nolan; David P Kelsell; Carl P Blobel; Karl S Lang; Philipp A Lang
Journal:  Sci Signal       Date:  2015-11-03       Impact factor: 8.192

6.  Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation.

Authors:  Yonka Christova; Colin Adrain; Paul Bambrough; Ashraf Ibrahim; Matthew Freeman
Journal:  EMBO Rep       Date:  2013-08-23       Impact factor: 8.807

Review 7.  Tylosis with oesophageal cancer: Diagnosis, management and molecular mechanisms.

Authors:  Anthony Ellis; Janet M Risk; Thiviyani Maruthappu; David P Kelsell
Journal:  Orphanet J Rare Dis       Date:  2015-09-29       Impact factor: 4.123

8.  Genetic interaction implicates iRhom2 in the regulation of EGF receptor signalling in mice.

Authors:  Owen M Siggs; Adam Grieve; Hongmei Xu; Paul Bambrough; Yonka Christova; Matthew Freeman
Journal:  Biol Open       Date:  2014-11-13       Impact factor: 2.422

9.  Tissue-specific role of RHBDF2 in cutaneous wound healing and hyperproliferative skin disease.

Authors:  Vishnu Hosur; Bonnie L Lyons; Lisa M Burzenski; Leonard D Shultz
Journal:  BMC Res Notes       Date:  2017-11-07

10.  iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function.

Authors:  Matthew A Brooke; Sarah L Etheridge; Nihal Kaplan; Charlotte Simpson; Edel A O'Toole; Akemi Ishida-Yamamoto; Olivier Marches; Spiro Getsios; David P Kelsell
Journal:  Hum Mol Genet       Date:  2014-03-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.